Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Cooper

Showing results (241-250 of 324) with videos related to

Pageof 33
Sort By:
Antiviral Therapy|April 28, 2006
Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005)Mark A Boyd, Preeyaporn Srasuebkul, Mana Khongphattanayothin, et al.
Antiviral Therapy|January 25, 2006
Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosisReshma S Autar, Ferdinand W N M Wit, Jongkol Sankote, et al.
AIDS (London, England)|July 17, 2007
Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patientsReshma Saskia Autar, Ferdinand W N M Wit, Jongkol Sankote, et al.
The Journal of Infectious Diseases|October 31, 2009
Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapyJulian H Elliott, Khol Vohith, Sarun Saramony, et al.
European Journal of Immunology|April 23, 2014
Human antigen-specific CD4⁺ CD25⁺ CD134⁺ CD39⁺ T cells are enriched for regulatory T cells and comprise a substantial proportion of recall responsesNabila Seddiki, Laura Cook, Denise C Hsu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 30, 2006
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individualsMartin Markowitz, Javier O Morales-Ramirez, Bach-Yen Nguyen, et al.
The Lancet. HIV|August 9, 2017
Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysisSteve Kanters, Maria Eugenia Socias, Nicholas I Paton, et al.
Clinical Pharmacokinetics|December 31, 2015
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 StudyLaura Dickinson, Janaki Amin, Laura Else, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 1, 2010
HIV immune escape at an immunodominant epitope in HLA-B*27-positive individuals predicts viral load outcomePalanee Ammaranond, David J van Bockel, Kathy Petoumenos, et al.
The Lancet. Infectious Diseases|April 17, 2015
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study, Dianne Carey, Rebekah Puls, et al.
Pageof 33

Showing results (241-250 of 324) with videos related to

Sort By:
Pageof 33
Antiviral Therapy|April 28, 2006
Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005)Mark A Boyd, Preeyaporn Srasuebkul, Mana Khongphattanayothin, et al.
Antiviral Therapy|January 25, 2006
Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosisReshma S Autar, Ferdinand W N M Wit, Jongkol Sankote, et al.
AIDS (London, England)|July 17, 2007
Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patientsReshma Saskia Autar, Ferdinand W N M Wit, Jongkol Sankote, et al.
The Journal of Infectious Diseases|October 31, 2009
Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapyJulian H Elliott, Khol Vohith, Sarun Saramony, et al.
European Journal of Immunology|April 23, 2014
Human antigen-specific CD4⁺ CD25⁺ CD134⁺ CD39⁺ T cells are enriched for regulatory T cells and comprise a substantial proportion of recall responsesNabila Seddiki, Laura Cook, Denise C Hsu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 30, 2006
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individualsMartin Markowitz, Javier O Morales-Ramirez, Bach-Yen Nguyen, et al.
The Lancet. HIV|August 9, 2017
Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysisSteve Kanters, Maria Eugenia Socias, Nicholas I Paton, et al.
Clinical Pharmacokinetics|December 31, 2015
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 StudyLaura Dickinson, Janaki Amin, Laura Else, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 1, 2010
HIV immune escape at an immunodominant epitope in HLA-B*27-positive individuals predicts viral load outcomePalanee Ammaranond, David J van Bockel, Kathy Petoumenos, et al.
The Lancet. Infectious Diseases|April 17, 2015
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study, Dianne Carey, Rebekah Puls, et al.
Pageof 33